These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 7891807

  • 21. Lipoproteins and apolipoproteins during the progression of chronic renal disease.
    Grützmacher P, März W, Peschke B, Gross W, Schoeppe W.
    Nephron; 1988; 50(2):103-11. PubMed ID: 3221949
    [Abstract] [Full Text] [Related]

  • 22. Lipoprotein (a) levels in end-stage renal failure and renal transplantation.
    Barbagallo CM, Averna MR, Sparacino V, Galione A, Caputo F, Scafidi V, Amato S, Mancino C, Cefalù AB, Notarbartolo A.
    Nephron; 1993; 64(4):560-4. PubMed ID: 8366981
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of serum lipid abnormalities in chronic nephritis.
    Hirano H, Yamada Y, Otani H, Kodama N, Mune M, Yukawa S.
    Kidney Int Suppl; 1999 Jul; 71():S147-9. PubMed ID: 10412761
    [Abstract] [Full Text] [Related]

  • 24. The effect of change of renal replacement therapy on serum lipoprotein (a) concentration.
    Misra M, Webb AT, Reaveley DA, Doherty E, O'Donnell M, Seed M, Brown EA.
    Adv Perit Dial; 1997 Jul; 13():168-73. PubMed ID: 9360675
    [Abstract] [Full Text] [Related]

  • 25. Apo(a) phenotypes and lp(a) concentrations in renal transplant patients.
    Kandoussi AM, Hugue V, Cachera C, Hazzan M, Dracon M, Tacquet A, Noël C.
    Nephron; 1998 Oct; 80(2):183-7. PubMed ID: 9736817
    [Abstract] [Full Text] [Related]

  • 26. Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients.
    Yang WS, Kim SB, Min WK, Park S, Lee MS, Park JS.
    Nephrol Dial Transplant; 1995 Oct; 10(9):1668-71. PubMed ID: 8559487
    [Abstract] [Full Text] [Related]

  • 27. Effects of renal replacement therapy on plasma lipoprotein(a) levels.
    Rosas S, Joffe M, Wolfe M, Brayman K, Rader DJ.
    Am J Nephrol; 2008 Oct; 28(3):361-5. PubMed ID: 18057868
    [Abstract] [Full Text] [Related]

  • 28. De novo development of hypercholesterolemia and elevated high-density lipoprotein cholesterol: apoprotein A-I ratio in patients with chronic renal failure following kidney transplantation.
    Kobayashi N, Okubo M, Marumo F, Uchida H, Endo T, Nakamura H.
    Nephron; 1983 Oct; 35(4):237-40. PubMed ID: 6417553
    [Abstract] [Full Text] [Related]

  • 29. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure.
    Stenvinkel P, Heimbürger O, Tuck CH, Berglund L.
    Kidney Int; 1998 May; 53(5):1336-42. PubMed ID: 9573549
    [Abstract] [Full Text] [Related]

  • 30. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism.
    Black IW, Wilcken DE.
    Clin Chem; 1992 Mar; 38(3):353-7. PubMed ID: 1547551
    [Abstract] [Full Text] [Related]

  • 31. Hyperlipidemia in children: the role of uremia, steroids and cyclosporine therapy.
    Singh A, Tejani A.
    Nephron; 1996 Mar; 74(3):529-35. PubMed ID: 8938676
    [Abstract] [Full Text] [Related]

  • 32. Lipoprotein abnormalities in chronic haemodialysis patients.
    Parsy D, Dracon M, Cachera C, Parra HJ, Vanhoutte G, Tacquet A, Fruchart JC.
    Nephrol Dial Transplant; 1988 Mar; 3(1):51-6. PubMed ID: 3132640
    [Abstract] [Full Text] [Related]

  • 33. Autoantibodies against oxidized LDL in chronic renal failure: role of renal function, diet, and lipids.
    Bergesio F, Monzani G, Ciuti R, Cirami C, Martinelli F, Salvadori M, Tosi PL.
    Nephron; 2001 Feb; 87(2):127-33. PubMed ID: 11244306
    [Abstract] [Full Text] [Related]

  • 34. [Lipoprotein (a) is a risk factor for cerebrovascular accident in patients with chronic renal failure].
    Ishikawa H.
    Nihon Jinzo Gakkai Shi; 1994 Jul; 36(7):846-52. PubMed ID: 8072223
    [Abstract] [Full Text] [Related]

  • 35. High-density lipoprotein in chronic renal failure and after renal transplantation.
    Savdie E, Gibson JC, Stewart JH, Simons LA.
    Br Med J; 1979 Apr 07; 1(6168):928-30. PubMed ID: 219935
    [Abstract] [Full Text] [Related]

  • 36. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency.
    Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, Weiss L, Wedel H, Alaupovic P.
    Nephrol Dial Transplant; 1997 Sep 07; 12(9):1908-15. PubMed ID: 9306342
    [Abstract] [Full Text] [Related]

  • 37. [Alterations of Lp (a) lipoprotein in patients with chronic renal failure treated by continuous ambulatory peritoneal dialysis].
    Takegoshi T, Kitoh C, Shimada T, Kawai K, Yamazaki Y, Mabuchi H.
    Nihon Jinzo Gakkai Shi; 1993 Jun 07; 35(6):757-63. PubMed ID: 8377289
    [Abstract] [Full Text] [Related]

  • 38. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
    Navarro JF, Mora C, Muros M, García-Idoate G.
    Nephron Clin Pract; 2003 Jun 07; 95(4):c128-35. PubMed ID: 14694274
    [Abstract] [Full Text] [Related]

  • 39. Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients.
    Kooshki A, Taleban FA, Tabibi H, Hedayati M.
    Ren Fail; 2011 Jun 07; 33(9):892-8. PubMed ID: 21859401
    [Abstract] [Full Text] [Related]

  • 40. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
    Milionis HJ, Elisaf MS, Karabina SA, Bairaktari E, Tselepis AD, Siamopoulos KC.
    Kidney Int; 1999 Dec 07; 56(6):2276-85. PubMed ID: 10594806
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.